Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Carla Damaschin,Dennis A Eichenauer,Stefanie Kreissl,Max S Topp,Stephan Mathas,Andreas Zimmermann,Vladan Vucinic,Annette Plütschow,Frank Breywisch,Michael Fuchs,Andreas Engert,Bastian Von Tresckow,Helen Goergen,Peter Borchmann,Martin Sökler,Julia Meissner

doi:10.1038/s41375-021-01386-z

Abstract

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Highlights

Carla Damaschin1,2, Helen Goergen1,2, Stefanie Kreissl1,2, Annette Plütschow1,2, Frank Breywisch3, Stephan Mathas 4, Julia Meissner5, Martin Sökler6, Max Peter Borchmann1,2
The BrECAPP and BrECADD protocols were investigated in a randomized phase II study including patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (HL)
Baseline characteristics were consistent with the randomized German Hodgkin Study Group (GHSG) HD15 and HD18 studies for advanced-stage HL [1, 2]

Summary

Introduction

Carla Damaschin1,2, Helen Goergen1,2, Stefanie Kreissl1,2, Annette Plütschow1,2, Frank Breywisch3, Stephan Mathas 4, Julia Meissner5, Martin Sökler6, Max Peter Borchmann1,2. The BrECAPP (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, procarbazine, prednisone) and BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) protocols were investigated in a randomized phase II study including patients with newly diagnosed advanced-stage classical HL (cHL). PFS was defined as the time between randomization and progression or relapse of cHL or death from any cause and was censored at the date of last information on the disease status.

Results

Conclusion